2487 Stock Overview
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Cutia Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.97 |
| 52 Week High | HK$18.26 |
| 52 Week Low | HK$3.73 |
| Beta | 0 |
| 1 Month Change | 31.79% |
| 3 Month Change | -31.22% |
| 1 Year Change | -10.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2487 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 21.3% | 2.2% | 4.3% |
| 1Y | -10.8% | 13.2% | 28.1% |
Return vs Industry: 2487 underperformed the Hong Kong Biotechs industry which returned 13.2% over the past year.
Return vs Market: 2487 underperformed the Hong Kong Market which returned 28.1% over the past year.
Price Volatility
| 2487 volatility | |
|---|---|
| 2487 Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.8% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 2487's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2487's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 360 | Lele Zhang | www.cutiatx.com |
Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company’s products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment; CU-10201, a topical 4% minocycline foam, approved for acne vulgaris treatment; and CU-10101, a topical novel small molecule agent, and a non-hormonal and small molecule drug for the treatment of mild to moderate atopic dermatitis.
Cutia Therapeutics Fundamentals Summary
| 2487 fundamental statistics | |
|---|---|
| Market cap | HK$1.90b |
| Earnings (TTM) | -HK$562.54m |
| Revenue (TTM) | HK$213.34m |
8.9x
P/S Ratio-3.4x
P/E RatioIs 2487 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2487 income statement (TTM) | |
|---|---|
| Revenue | CN¥198.86m |
| Cost of Revenue | CN¥98.77m |
| Gross Profit | CN¥100.08m |
| Other Expenses | CN¥624.43m |
| Earnings | -CN¥524.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 50.33% |
| Net Profit Margin | -263.68% |
| Debt/Equity Ratio | 17.7% |
How did 2487 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 14:50 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cutia Therapeutics is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhuonan Xu | China International Capital Corporation Limited |
| Hangci Zheng | China International Capital Corporation Limited |
| Yifan Du | Citic Securities Co., Ltd. |